Sacubitril Valsartan (Entresto) prior authorization at Priority Health
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Priority Health requires prior-authorization documentation for Sacubitril Valsartan (Entresto): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Priority Health reviews Sacubitril Valsartan (Entresto) prior authorizations against its medical policy . Priority Health-specific context: Subsidiary of Corewell Health (Michigan integrated health system, formed from Beaumont + Spectrum 2022); ~1.3M members. Second-largest insurer in Michigan after BCBS Michigan. Michigan DIFS oversight.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Priority Health's medical policy URL referenced in the cover letter
Priority Health's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- West Michigan narrow-network restrictions
- Step therapy on specialty drugs
- Medicare Advantage Part B drug step therapy
- Behavioral health network adequacy
Sacubitril Valsartan (Entresto)-specific denial patterns and context
Across payers (not just Priority Health), Sacubitril Valsartan (Entresto)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Step therapy requiring ACE-I or ARB trial first (per ESC/AHA guidelines — defensible)
- LVEF threshold disputes
- HFpEF indication denied despite FDA expansion (2021)
Brand: Entresto. ARNI (angiotensin receptor-neprilysin inhibitor). PARADIGM-HF for HFrEF; PARAGON-HF supported expanded HFpEF/HFmrEF approval (2021). Generic launches expected mid-2025 following patent litigation outcome.
Manufacturer patient-assistance program: Novartis Patient Assistance Foundation — relevant when a Priority Health denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Priority Health gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.priorityhealth.com/provider) with the same packet plus a peer-reviewed citation supporting Sacubitril Valsartan (Entresto)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Priority Health denial on DenialHelp.
Contact Priority Health
- Provider portal: https://www.priorityhealth.com/provider
Frequently asked questions
What documentation does Priority Health need for Sacubitril Valsartan (Entresto) prior auth?
Priority Health's typical PA packet for Sacubitril Valsartan (Entresto): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Priority Health?
Standard Sacubitril Valsartan (Entresto) PA decisions at Priority Health: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Priority Health most often reject Sacubitril Valsartan (Entresto) for?
Across Priority Health's book the common rejection patterns include: West Michigan narrow-network restrictions; Step therapy on specialty drugs; Medicare Advantage Part B drug step therapy. For Sacubitril Valsartan (Entresto) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Priority Health on Sacubitril Valsartan (Entresto)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Sacubitril Valsartan (Entresto) PA packet
Open ApprovalHelp — generate a Sacubitril Valsartan (Entresto) prior-auth packet tailored to Priority Health's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com